Out-thinking industry

Some of the most innovative thinking on display at this year’s American Society of Clinical Oncology meeting came not from cancer companies, but from FDA and groups of oncologists and patient advocates who are busy rethinking how cancer drugs should be developed.

The meeting was chock-a-block with data readouts showing impressive response rates to innovative new therapies, and even included reports from one company taking an unquestionably novel tissue-agnostic approach to designing a clinical development program (see “Big Results in Small Cancers”)...